NYSE American - Nasdaq Real Time Price • USD
Actinium Pharmaceuticals, Inc. (ATNM)
As of 2:46 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 4 |
| Avg. Estimate | -0.52 | -0.55 | -1.92 | -0.11 |
| Low Estimate | -0.65 | -0.69 | -2.66 | -0.82 |
| High Estimate | -0.42 | -0.46 | -1.33 | 0.97 |
| Year Ago EPS | -0.43 | -0.58 | -1.83 | -1.92 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | 71.53M |
| Low Estimate | -- | -- | -- | 28.97M |
| High Estimate | -- | -- | -- | 141.3M |
| Year Ago Sales | -- | -- | 81k | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.42 | -0.48 | -0.53 | -0.54 |
| EPS Actual | -0.43 | -0.58 | -0.49 | -0.34 |
| Difference | -0.01 | -0.1 | 0.04 | 0.2 |
| Surprise % | -2.40% | -20.80% | 7.50% | 37.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.52 | -0.55 | -1.92 | -0.11 |
| 7 Days Ago | -0.45 | -0.47 | -1.73 | 0.04 |
| 30 Days Ago | -0.61 | -0.63 | -1.86 | -0.23 |
| 60 Days Ago | -0.61 | -0.63 | -1.89 | -0.23 |
| 90 Days Ago | -0.61 | -0.63 | -1.9 | -0.2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | 1 | 2 | 2 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | ATNM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -20.90% | -- | -- | 0.80% |
| Next Qtr. | 5.20% | -- | -- | 9.60% |
| Current Year | -4.90% | -- | -- | 4.50% |
| Next Year | 94.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
| Maintains | Maxim Group: Buy to Buy | 3/19/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 |
Related Tickers
TGTX TG Therapeutics, Inc.
13.35
-4.57%
OTLK Outlook Therapeutics, Inc.
8.05
-2.90%
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9780
-1.39%
KPTI Karyopharm Therapeutics Inc.
1.1450
-10.55%
CRDF Cardiff Oncology, Inc.
4.3100
-1.38%
AXSM Axsome Therapeutics, Inc.
66.81
+1.66%
SLS SELLAS Life Sciences Group, Inc.
1.5250
+0.33%
LPCN Lipocine Inc.
5.39
-1.01%
EYEN Eyenovia, Inc.
0.5670
+6.77%
MDGL Madrigal Pharmaceuticals, Inc.
207.54
-6.62%